Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds-Reference-Cited by-同舟云学术

Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds

Published:2019-11-06 Issue:3 Volume:49 Page:457-467
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Härtig Florian,Poli Sven,Ebner Matthias,Birschmann Ingvild,Kuhn Joachim,Ziemann Ulf,Häring Hans-Ulrich,Lehmann Rainer,Peter Andreas,Hörber Sebastian^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11239-019-01981-z.pdf

Reference41 articles.

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561

2. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352. https://doi.org/10.1056/NEJMoa0906598

3. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ, Investigators R-MT, Investigators R-ST (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709–718. https://doi.org/10.1056/NEJMoa1113697

4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962. https://doi.org/10.1016/S0140-6736(13)62343-0

5. Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK, GARFIELD-AF Investigators (2016) Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol 174(4):610–623. https://doi.org/10.1111/bjh.14084

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC–MS for plasma level dabigatran quantification: Results from DRIVING study;International Journal of Laboratory Hematology;2023-09-14

2. Direct Oral Anticoagulants: Laboratory Challenges and Antidotes;Hämostaseologie;2023-02

3. Intravenous Thrombolysis With Alteplase at 0.6 mg/kg in Patients With Ischemic Stroke Taking Direct Oral Anticoagulants;Journal of the American Heart Association;2022-10-04

4. Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia;Life;2022-06-28

5. Author Reply to “Intravenous thrombolysis in patients taking direct oral anticoagulants (European stroke organisation intravenous thrombolysis guidelines comment);European Stroke Journal;2021-11-15